A patient with HIV/AIDS who received transplanted stem cells edited with CRISPR to have a mutation that blocks HIV is living without side effects, providing evidence that the gene-editing technology can safely target HIV, according to a case study published Wednesday in the New England Journal of Medicine.

American Health Line rounds up the latest health care news in the states.

Researchers are increasingly interested in the connection between the gut microbiome and obesity, but a new study from researchers at Massachusetts General Hospital suggests that transferring microbiota from a lean donor to an obese recipient might not improve the recipients' metabolic health, contrary to other research.

The Federal Trade Commission on Tuesday announced that it has warned three companies for advertising that their cannabidiol products can treat medical conditions without evidence to support those claims.

FDA recently released draft guidance that calls on researchers to include more male patients in clinical trials for breast cancer therapies in response to concerns that men are missing out on lifesaving treatments.

Google on Friday announced a new policy banning advertisements for "unproven or experimental medical techniques," including most cellular, gene, and stem cell therapies.

Dawn Patterson and two of her children have a rare bone disease, and the only treatment is a drug that was slated to cost $6 million a year—a high price tag that observers say is indicative of the pharmaceutical industry's growing interest in treatment for rare diseases.

The Drug Enforcement Administration on Monday announced that it will move forward with a years-delayed expansion of the agency's marijuana research program, meaning the agency soon could permit more growers to produce marijuana for use in medical studies and other research.

Two experts in a Wall Street Journal opinion piece published last week argued that it is time to abandon biosimilars in favor of leveraging federal price regulation to create more affordable biologic drugs—but the piece drew a rebuttal from former FDA Commissioner Scott Gottlieb, who argued Congress could enact policy changes to make biosmilars more competitive with their biologic counterparts.

Scientists at Weill Cornell Medicine are trying to use the gene-editing technology CRISPR to edit DNA within human sperm, but some experts are questioning whether the practice is ethical.